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Abstract: 
New psychoactive substances (NPS) are commonly referred to as “research 
chemicals”, “designer drugs” or “legal highs.” One NPS class is represented 
by dissociative anesthetics, which include analogues of the 
arylcyclohexylamine phencyclidine (PCP), ketamine, and diphenidine. A 
recent addition to the NPS market was 4-[1-(3-
methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo), a morpholine 
analogue of 3-MeO-PCP. Although suspected to have dissociative effects in 
users, information about its pharmacological profile is not available. From 
clinical and forensic perspectives, detailed analytical data are needed for 
identification, especially when facing the presence of positional isomers, as 
these are frequently unavailable commercially. This study presents the 
analytical and pharmacological characterization of 3-MeO-PCMo along with 
five additional analogues including the 2- and 4-MeO- isomers, 3,4-
methylenedioxy-PCMo (3,4-MD-PCMo), 3-Me-PCMo and PCMo. All six 
arylcyclohexylmorpholines were synthesized and characterized by 
chromatographic, mass spectrometric and spectroscopic techniques. The 
three positional isomers could be differentiated and the identity of 3-MeO-
PCMo obtained from an internet vendor was verified. All six compounds 
were also evaluated for affinity at 46 central nervous system receptors 
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including the N-methyl-D-aspartate receptor (NMDAR), an important target 
for dissociative anesthetics such as PCP and ketamine. In vitro binding 
studies using [3H]-MK-801 in rat forebrain preparations revealed moderate 
affinity for NMDAR in the rank order of 3-Me > 3-MeO >PCMo > 3,4-MD > 
2-MeO > 4-MeO-PCMo. 3-MeO-PCMo was found to have moderate affinity 
for NMDAR comparable to that of ketamine, and had an approximate 12-
fold lower affinity than PCP. These results support the anecdotal reports of 
dissociative effects from 3-MeO-PCMo in humans.  
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Abstract 
New psychoactive substances (NPS) are commonly referred to as “research chemicals”, 
“designer drugs” or “legal highs.” One NPS class is represented by dissociative anesthetics, 
which include analogues of the arylcyclohexylamine phencyclidine (PCP), ketamine, and 
diphenidine. A recent addition to the NPS market was 4-[1-(3-
methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo), a morpholine analogue of 3-MeO-PCP. 
Although suspected to have dissociative effects in users, information about its pharmacological 
profile is not available. From clinical and forensic perspectives, detailed analytical data are 
needed for identification, especially when facing the presence of positional isomers, as these 
are frequently unavailable commercially. This study presents the analytical and pharmacological 
characterization of 3-MeO-PCMo along with five additional analogues including the 2- and 4-
MeO- isomers, 3,4-methylenedioxy-PCMo (3,4-MD-PCMo), 3-Me-PCMo and PCMo. All six 
arylcyclohexylmorpholines were synthesized and characterized by chromatographic, mass 
spectrometric and spectroscopic techniques. The three positional isomers could be 
differentiated and the identity of 3-MeO-PCMo obtained from an internet vendor was verified. All 
six compounds were also evaluated for affinity at 46 central nervous system receptors including 
the N-methyl-D-aspartate receptor (NMDAR), an important target for dissociative anesthetics 
such as PCP and ketamine. In vitro binding studies using [3H]-MK-801 in rat forebrain 
preparations revealed moderate affinity for NMDAR in the rank order of 3-Me > 3-MeO >PCMo 
> 3,4-MD > 2-MeO > 4-MeO-PCMo. 3-MeO-PCMo was found to have moderate affinity for 
NMDAR comparable to that of ketamine, and had an approximate 12-fold lower affinity than 
PCP. These results support the anecdotal reports of dissociative effects from 3-MeO-PCMo in 
humans.  
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Introduction 
A high number of new psychoactive substances (NPS)[1] continue to be available from online 
vendors and are sold as “research chemicals”. These chemicals are largely designed to by-pass 
governmental restrictions on existing psychoactive drugs. Dissociative agents that target the N-
methyl-D-aspartate receptor (NMDAR) represent one of many available classes of compounds 
that are encompassed by the NPS term. Substances with dissociative profile (Figure 1A) 
comprise structural analogues of the arylcyclohexylamines such as phencyclidine (PCP), 
ketamine and methoxetamine.[2] More recently, 1,2-diarylethylamines such as diphenidine and 
its 2-methoxy analogue 2-MXP have also appeared.[3,4]  
Substances that target the NMDAR are of interest for the development of treatment options for 
conditions such as depression, neuropathic pain, and a variety of neurodegenerative disorders 
and dementias.[5-9] At the same time, a number of these substances are used recreationally, 
outside of a medical setting, and include compounds that have not undergone any substantial 
pharmacological and toxicological evaluations. A systematic methodology is needed in order to 
address the chemical, pharmacodynamic, and pharmacokinetic properties of these 
substances,[3,4,10,11] thus facilitating drug development efforts, and identification of toxicity 
profiles as well as adverse events associated with recreational drug use.[12-14] 
The earliest reported synthesis of 4-(1-phenylcyclohexyl)morpholine (PCMo) was found in a 
patent submitted in 1954[15] and predates that of PCP,[16] however, its pharmacology, or 
dissociative profile, was not recognized at that time. PCMo made brief documented 
appearances as an “analog” of PCP in the recreational market during the 1970’s and again in 
the early 2000’s.[2] More recently, 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) 
has become available for purchase as a “research chemical” on a number of websites, which 
encouraged the authors to explore its chemistry and pharmacology. To gain further insight into 
this class of compounds, 2-MeO- and 4-MeO positional isomers were synthesized, as well as 
3,4-methylenedioxy-PCMo (3,4-MD-PCMo), 3-Me-PCMo, and the unsubstituted PCMo template 
(Figure 1B). The entire series was subjected to comprehensive analytical characterization 
including chromatographic, mass spectrometric and spectroscopic methods. In addition, a test 
purchase of 3-MeO-PCMo was compared to the synthesized reference material confirming its 
identity.   
With the exception of 2-MeO-PCMo and PCMo, pharmacological data on the 
arylcyclohexylmorpholines investigated in the present study are not available. 2-MeO-PCMo 
was shown to reduce acute thermal (tail immersion test) and chronic chemical pain 
(formaldehyde) induced in adult female rats. [17] In the tail immersion test, analgesic effects were 
found to be more pronounced compared to PCP and PCMo.[17] PCMo was also demonstrated to 
display lower potencies compared to PCP in a range of in vitro and in vivo assays targeting a 
number of different receptors.[18-29] In order to explore whether the six arylcyclohexylmorpholines 
showed PCP or ketamine-like properties in vitro, all test drugs were pharmacologically 
characterized in the present study for binding affinity at 46 CNS receptors including NMDAR, 
and monoamine transporters for dopamine, norepinephrine and serotonin. 
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Experimental 
Materials 
 
All starting materials, reagents, and solvents used for syntheses were obtained from Sigma 
Aldrich (St. Louis, MO, USA). Flash column chromatography was performed using Merck silica 
gel grade 9385 (230-400 mesh, 60 Å). Melting points were obtained using a DigiMelt A160 SRS 
digital melting point apparatus (Stanford Research Systems, Sunnyvale, CA, USA) at a ramp 
rate of 2°C/min. Melting points, spectral analyses, and receptor binding studies were performed 
on target compounds following flash chromatography purification.  
Instrumentation 
Nuclear magnetic resonance (NMR) spectroscopy 
1H (400 MHz) and 13C NMR spectra (101 MHz) were obtained from the freebase material 
in CDCl3 solution (100% and 99.96% D, 0.03% (v/v) TMS) at a concentration of 20 mg/mL using 
a Bruker Ultrashield 400 plus spectrometer with a 5 mm BBO S1 (Z gradient plus) probe at 
24°C. Internal chemical shift references were TMS (δ = 0.00 ppm) and CDCl3 (δ = 77.0 ppm). 
Spectra were recorded with the freebases and the test purchase of 3-MeO-PCMo was 
determined to be the freebase. NMR assignments were made as described previously[10,30,31] 
using chemical shift position, splitting, 13C PENDANT and 2-D experiments (HMQC, HMBC, and 
COSY).  
Gas chromatography (EI/CI) ion trap mass spectrometry 
 
Data for all six PCMo analogues (0.5 mg/mL in methanol) were recorded under full scan 
electron (EI) and chemical ionization (CI) conditions using HPLC grade methanol as the liquid 
CI reagent. A Varian 450-GC gas chromatograph coupled to a Varian 220-MS ion trap mass 
spectrometer (scan range m/z 41– m/z 500) and a Varian 8400 autosampler was employed with 
a Varian CP-1177 injector (275ºC) in split mode (1:50) (Walnut Creek, CA, USA). The Varian 
MS Data Review function of the Workstation software, version 6.91, was used for data 
acquisition. Transfer line, manifold and ion trap temperatures were set at 310, 80 and 220ºC, 
respectively. The carrier gas was helium at a flow rate of 1 mL/min using the EFC constant flow 
mode. The default settings for CI ionization parameters (0.4 s/scan) were used: CI storage level 
m/z 19.0; ejection amplitude m/z 15.0; background mass m/z 55; maximum ionization time 2000 
µs; maximum reaction time 40 ms; target TIC 5000 counts. An Agilent J&W VF-5ms GC column 
(30 m × 0.25 mm, 0.25 µm) was employed for separation. The starting temperature was set at 
80ºC and held for 1 min. The temperature then increased at 20ºC/min to 280ºC and held 
constant for 9.0 min to give a total run time of 20.00 min. 
High mass accuracy mass spectrometry using an atmospheric solids analysis probe (ASAP) 
ASAP was employed with a Thermo Fisher Scientific Inc., (Waltham, MA, USA) Orbitrap 
Exactive using an Ion Max source in positive mode. Measured accurate masses were within ± 5 
ppm of the theoretical masses. The following parameters were used: resolution was set to ultra-
high, sheath gas (N2) flow 5 (arbitrary units), auxiliary gas flow 6 (arbitrary units), sweep gas 
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 5 
flow 0 (arbitrary units), corona discharge 4 kV, capillary temperature 275 °C, capillary voltage 
25.0 V, skimmer voltage 14 V and a tube lens voltage of 85 V. Instrument calibrations were 
performed using the ProteoMass LTQ/FT-Hybrid ESI Positive Mode Calibration Mix from 
Supelco Analytical (Bellefonte, PA, USA).  
Ultra-high performance liquid chromatography (UHPLC) high mass accuracy electrospray mass 
spectrometry  
Mobile phases used for UHPLC separation consisted of acetonitrile with 1% formic acid (v/v) 
and an aqueous solution of 1% formic acid. The column temperature was set at 40°C (0.6 
mL/min) and data were acquired for 5.5 min. The elution was a 5–70% acetonitrile gradient 
ramp over 3.5 min, then increased to 95% acetonitrile in 1 min and held for 0.5 min before 
returning to 5% acetonitrile in 0.5 min. QTOF-MS data were acquired in positive mode scanning 
from m/z 100–m/z 1000 with and without auto MS/MS fragmentation. Ionization was achieved 
with an Agilent JetStream electrospray source and infused internal reference masses. Agilent 
6540 QTOF-MS parameters: gas temperature 325°C, drying gas 10 L/min and sheath gas 
temperature 400 °C. Internal reference ions at m/z 121.05087 and m/z 922.00979 were used.   
High performance liquid chromatography diode array detection 
HPLC-DAD analyses were carried out on a Dionex 3000 Ultimate system coupled to a UV diode 
array detector (Thermo Fisher, St Albans, UK), using a Phenomenex Synergi Fusion column 
(150 mm x 2 mm, 4 µm) that was protected by a 4 mm x 3 mm Phenomenex Synergi Fusion 
guard column (Phenomenex, Macclesfield, UK). The mobile phases were made from 70% 
acetonitrile with 25 mM triethylammonium phosphate (TEAP) buffer and an aqueous solution of 
25 mM TEAP buffer. Elution was achieved with a gradient that started with 4% acetonitrile and 
ramped to 70% acetonitrile in 15 min and held for 3 min. The total acquisition time was 18 min 
at a flow rate of 0.6 mL/min. The diode array detection window was set at 200 nm to 595 nm 
(collection rate 2 Hz). 
Infrared spectroscopy 
Infrared (IR) spectra were obtained on a Perkin Elmer Spectrum BX FTIR model (Llantrisant, 
UK) using a Pike MIRacle ATR system. Data were acquired with the Spectrum v5.01 software 
(scan range 4000–400 cm-1, resolution 4 cm-1, 16 scans). Spectral data can be found in 
Supporting Information.  
Microwave synthesizer  
Conversion from primary amine intermediate to morpholine-ring products were performed using 
a CEM Discover SP microwave synthesizer (CEM Corporation, Matthews NC, USA). Reactions 
were carried out in 35 mL microwave vessels from CEM. Conditions for the reactions are 
detailed below.  
Syntheses procedures 
The syntheses of the primary amine intermediates were performed using a modified Geneste 
route (Figure 2) as described previously.[5,10,32] Reactions starting from the primary amine 
Page 6 of 25
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 6 
intermediate to yield the morpholine ring products were carried out in a CEM Discover SP 
microwave synthesizer. The primary amine (PCA) intermediates were available from previous 
studies.[5,10,30]  
Preparation of 4-[1-(2-methoxyphenyl)cyclohexyl]morpholine (2-MeO-PCMo) 
1-(2-Methoxyphenyl)cyclohexanamine (2-MeO-PCA) (4.87 mmol, 1.00 g) and triethylamine 
(14.61 mmol, 2.03 mL) were added to acetonitrile (~15 mL). The solution was dried for 10 
minutes with 4Å molecular sieves and then decanted into a 35 mL microwave vessel. 2-
Bromoethyl ether (9.74 mmol, 1.22 mL) was added to the solution, the vessel was sealed under 
inert argon, and then reacted for 1.5 h at 85°C with 50 W power and stirring. Reaction pressures 
did not exceed 25 psi. Afterwards, the reaction mixture (a red/dark red color) was transferred to 
an aqueous 0.2 M HCl solution (60 mL) and washed with ethyl acetate (EtOAc) (3 x 60 mL). The 
aqueous phase was basified to pH >12 with KOH pellets and extracted with EtOAc (3 x 60 mL). 
The pooled organic extraction was washed once with 10 mL brine, dried with anhydrous 
magnesium sulfate, and concentrated under reduced pressure to produce a light amber oil. The 
crude product was collected and purified using flash column chromatography with a mobile 
phase consisting of hexane/EtOAc (80/20) with TEA (1%, v/v). Fractions containing the product 
were pooled and concentrated to yield light-yellow oil, which solidified upon cooling (3.16 mmol, 
0.869 g, 64.7% yield). This solid was recrystallized from boiling hexanes. Upon cooling at 0°C, 
colorless crystals formed and were collected by decanting, washed with hexanes, and dried at 
room temperature (m.p. 67.1–68.6°C). HR-ASAP-MS of the freebase observed: m/z 276.1949 
(theory [M+H]+ C17H26NO2
+, m/z 276.1958, ∆ = -3.3 ppm). 
The HCl salt of 2-MeO-PCMo was prepared by dissolving the solidified freebase in 100% 
ethanol (EtOH), titrating to pH 1.0 with concentrated HCl, and evaporating under a stream of 
warm air. EtOH (100%) was added in 10 mL increments and evaporated until all residual 
moisture and HCl were removed. The resulting solid was dried and washed with EtOAc (2 x 5 
mL). The dried solid was then recrystallized by dissolving in a minimal amount of warm EtOH 
and diluted 3-fold with Et2O. The solution was stored at 0°C overnight. The resulting crystals 
were collected by decanting the solvent, washing the solid with EtOAc (2 x 5 mL) and drying. 
Recrystallization was repeated 2 additional times as described to produce white flakey crystals 
with m.p. 179.5–181.5°C (lit. 167–169°C[17]).  
Preparation of 4-[1-(3-Methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) 
3-MeO-PCMo was prepared in 50.9% yield from 3-MeO-PCA as described above and formed a 
colorless crystalline solid (m.p. 74.4–75.3°C) HR-ASAP-MS of the freebase observed: m/z 
276.1952 (theory [M+H]+ C17H26N1O2
+, m/z 276.1958, ∆ = -2.2 ppm). The HCl salt was a white 
flakey crystalline powder (m.p. 209.1–209.4°C). 
Preparation of 4-[1-(4-methoxyphenyl)cyclohexyl]morpholine (4-MeO-PCMo) 
4-MeO-PCMo was prepared in 43% yield from 4-MeO-PCA as described above and formed a 
colorless crystalline solid (m.p. 79.9–81.5°C). HR-ASAP-MS of the freebase observed: m/z 
276.1951 (theory [M+H]+ C17H26N1O2
+, m/z 276.1958, ∆ = -2.5 ppm). The HCl salt formed 
translucent amber crystals (m.p. 153.1–156.1°C). 
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Preparation of 4-[1-(1,3-benzodioxol-5-yl)cyclohexyl]morpholine (3,4-MD-PCMo) 
 
3,4-MD-PCMo was prepared in 44% yield from 3,4-MD-PCA as described above and formed a 
colorless crystalline solid (m.p. 123.4–124.9°C). HR-ASAP-MS of the freebase observed: m/z 
290.1752 (theory [M+H]+ C17H26N1O2
+, found m/z 290.1751, ∆ = 0.3 ppm). The HCl salt was a 
white fluffy crystalline powder (m.p. 180.5–181.7°C). 
Preparation of 4-[1-(3-methylphenyl)cyclohexyl]morpholine (3-Me-PCMo) 
3-Me-PCMo was prepared in 46.4% yield from 3-Me-PCA as described above as a colorless oil. 
The HCl salt was a white fluffy crystalline powder (m.p. 211.2–211.7°C). HR-ASAP-MS of the 
HCl salt observed: m/z 260.2018 (theory [M+H]+ C17H26N1O2
+, m/z 260.2009, ∆ = 3.5 ppm). 
Preparation of 4-(1-phenylcyclohexyl)morpholine (PCMo) 
PCMo was prepared as described in 60% yield from PCA; however, microwave reaction 
parameters were slightly altered (80°C, 65 W, and monitored by GC-MS for a total reaction time 
of 2.5 h). HR-ASAP-MS of the freebase observed: m/z 246.1845 (theory [M+H]+ C17H26N1O2
+, 
m/z 246.1852, ∆ = 2.8 ppm). HCl salt was obtained as the hemihydrate (1H NMR) white powder 
with a melting point of 197.3–198.5°C (lit. 187–188°C[17]; 188–190°C;[33] 187–188°C;[34] 181–
182°C;[35] 199–201°C (hemihydrate);[36] 182°C[15]). An alternate route for the synthesis of PCMo 
was also employed and is provided as Supporting Information.  
NMDA receptor binding studies 
 
In vitro binding affinities (Ki) of the target compounds were determined using competitive 
radioligand binding studies with [3H]-MK-801, a high-affinity ligand for the PCP site within the 
NMDAR channel, in accordance with established protocols.[37,38] Thoroughly washed rat 
forebrain homogenate was used as the NMDAR source (whole brain obtained from Pel-Freez 
Biologicals, Rogers AR, USA) and prepared as described by Reynolds and Sharma[37].  
Suspensions of 10 mM HEPES buffer (pH 7.4, 25oC) containing 100 µg/mL protein, 1 nM [3H]-
MK-801, 100 µM glutamate, 10 µM glycine, and various concentrations of unlabeled test drugs 
were incubated in the dark on a mechanical rocker at 25oC for 2 h. (+)-MK-801 (30 µM) was 
used for nonspecific binding (and positive control). The reaction was terminated by vacuum 
filtration using a 24-well cell harvester (Brandel, Gaithersburg MD, USA) over presoaked GF/B 
glass fiber filters (Brandel, Gaithersburg, MD, USA).  Filters were washed with room 
temperature HEPES buffer (3 x 5 mL). Tritium trapped on the filter was measured via liquid 
scintillation counting, using a Beckman LS 6500 multipurpose scintillation counter 
(BeckmanCoulter, USA) at 57% efficiency. IC50 values were determined with Graphpad Prism 
5.0 (GraphPad Software, La Jolla, USA) using non-linear regression with log-concentration 
plotted against percent specific binding. Percent specific binding for [3H]-MK-801 in a control 
experiment was ~95%. Ki values were calculated using the equation of Cheng and Prusoff.
[39] 
The Kd for (+)-MK-801 (1.75 nM), was determined via a homologous binding assay as described 
by Reynolds and Sharma and was consistent with the literature.[38] Protein concentration was 
determined via the Bradford method[40] using Coomassie protein assay reagent and rat albumin 
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as standard (Sigma Aldrich, USA). Experiments were performed in duplicate and repeated three 
times.  
 
Non-NMDA receptor binding studies 
 
Competitive binding studies of PCMo and analogues at 45 additional CNS receptors were 
performed through the National Institute of Mental Health Psychoactive Drug Screening 
Program (NIMH PDSP). Briefly, target compounds were dissolved in DMSO and subjected to 
primary screening at 10,000 nM concentrations. Compounds exhibiting >50 % inhibition 
underwent secondary assay at varying concentrations to determine Ki values. Additional 
experimental details are available in the NIMH PDSP assay protocol book.[41] 
 
Results and Discussion 
 
The six morpholine analogues investigated in this study (Figure 1B) were synthesized using the 
modified Geneste route as reported previously for the preparation of PCP and PCPy 
analogs.[5,10,32] The conversion from the primary amine (PCA) to the morpholine ring was 
performed using an SN2 cyclization reaction between the substituted PCA material and bis(2-
bromoethylether) (Figure 2) and gave ~45% yields following purification by column 
chromatography and recrystallization. The synthesized PCMo HCl was found to be the 
hemihydrate salt (1H NMR) and was consistent with a literature melting point value reported for 
the hemihydrate salt.[36] The remaining analogues contained less than a 0.25 molar equivalent 
of water. A discrepancy with the 2-MeO PCMo HCl melting point exists herein with a previously 
reported value,[17] which may be due to polymorphism, solvates or purity. The appearance of 3-
MeO-PCMo on the “research chemicals” market triggered questions about the ability to 
differentiate this compound from its positional 2-MeO-PCMo and 4-MeO-PCMo isomers, given 
that isomeric sets of compounds are frequently unavailable as reference material that can be 
used for forensic and clinical investigations. With the exception of 2-MeO-PCMo and PCMo, 
where some, albeit limited analytical data are available, the r maining compounds presented in 
this study are reported for the first time.  
Gas chromatography ion trap mass spectrometry (GC-IT-MS) data obtained from electron 
ionization (EI) and chemical ionization (CI) methods recorded for the HCl salts are summarized 
in Figure 3. The positional isomers 2-, 3-, and 4-MeO-PCMo could be separated on the GC 
column (10.04, 10.30 and 10.52 min). Under EI conditions, both the molecular ion and a [M-H]+ 
species were visible in appreciable relative abundance and implementation of CI facilitated 
detection of the corresponding protonated molecules. The EI mass spectrum obtained in the 
present study for PCMo was comparable with a spectrum published 40 years ago[33] although 
differences were observed in the relative abundance of various fragment, possibly due to 
implementation of different mass analyzers. CI mass spectra of PCMo, using both methane and 
isobutane as the reagent gas, appeared 3-4 years later[42,43] which revealed the formation of 
fragment ions also detected in the present study, such as m/z 88, m/z 159 and m/z 202, 
respectively. The ions formed under EI and CI ion trap MS conditions appeared to be equivalent 
to those reported previously for a range of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-
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phenylcyclohexyl)pyrrolidine[10] and N-alkyl-arylcyclohexylamines[5] and proposed fragmentation 
pathways have been described. The implementation of GC-MS analysis also resulted in 
degradation of the PCMo products that gave rise to a GC-induced degradant consistent with 
what appeared to be a 1-(1-cyclohexen-1-yl)-ring-substituted benzene species which has been 
described for other PCP-type substances before[10] (Supporting Information). Conversion of the 
hydrochloride salts to the freebases and analysis by a different instrument (GC quadrupole EI-
MS) revealed a significant reduction in degradation (Supporting Information). The sample 
advertised as 3-MeO-PCMo by an online vendor was found to be consistent with the information 
provided on the product label. Implementation of GC-sIR also allows for the analysis of 
compound mixtures and/or substances that may only be available in small amounts, including 
the GC-induced degradation products (Supporting Information). As shown in the Supporting 
Information, the three positional isomers could be differentiated by ATR-IR (HCl salts) and GC-
sIR. The purity of the freebase was not determined; however, no impurity peaks were observed 
with GC-MS, LC-MS, or NMR, and the melting point of the test purchase exactly matched that of 
the synthesized 3-MeO-PCMo when run side by side. Attempts to separate the three positional 
isomers using various solvent combinations and two different TLC plates, however, were 
unsuccessful.  
Ultra-high performance liquid chromatography electrospray quadrupole time-of-flight tandem 
mass spectra for all six PCMo analogues are shown in Figure 4, which illustrated that product 
ion formations were also comparable to a number of PCP/PCPy[10] and N-alkyl-
arylcyclohexylamine analogues[5] Examples observed in Figure 4 include a neutral loss of 
morpholine, formation of the respective tropylium ion or detection of protonated morpholine. 
Implementation of the HPLC-diode array detection (DAD) procedure showed only partial 
separation of the three positional isomers due to co-elution of 3-MeO- and 4-MeO-PCMo 
(Figure 5). However, the ultraviolet spectra scanned between 200 and 594 nm provided distinct 
differences that allowed for facile differentiation between the isomers. 3-MeO-PCMo gave rise to 
distinctive peaks at 218 nm and 278 nm whereas 4-MeO-PCMo displayed a slight shift to 230 
nm although the 277 nm peak remained indistinguishable. UV spectra recorded for 3,4-MD-
PCMo, 3-Me-PCMo, and PCMo and their corresponding HPLC retention times are provided as 
Supporting Information.  
Detailed NMR analyses on PCMo have been reported previously and were consistent with the 
results presented in this study (Tables 1 and 2).[44,45] PCMo HCl was also characterized by 13C 
NMR and the recorded spectrum was in agreement with literature values.[36] In general, the 
chemical shift behavior of the series was consistent with those observed previously with related 
arylcyclohexylamines and a detailed discussion can be found elsewhere.[5,10,30] One notable 
distinction unique to the PCMo series worth addressing, however, is with respect to the 
morpholine ring, as this feature may be useful for the identification of related 
arylcyclohexylmorpholines. Due to the presence of the O heteroatom in the ring system, the β-
chemical shifts were more deshielded and, thus, appeared further downfield than those found in 
the α-position (NCH) in both the 1H (~3.6 ppm vs. ~2.3 ppm) and 13C spectra (~68 ppm vs. ~46 
ppm). In the 1H spectra, the β-protons consistently appeared as a triplet, integrating to four 
protons, due to vicinal coupling (J ~4.6 Hz) with the two α-protons (magnetically equivalent due 
to ring flipping). The occurrence of ring flipping appeared to be consistent with the fact that the 
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1H NMR spectra of the HCl salts (Supporting Information) showed separate axial and equatorial 
shifts for the beta protons. Protonation is known to prevent ring flipping, and this effect was 
observed with other compounds including arylcyclohexylamines.[10] Similarly, the α-protons 
appeared as a triplet due to vicinal coupling with the β-protons (J ~4.6 Hz). Furthermore, the 2,6 
and α-proton chemical shifts in 2-MeO-PCMo appeared further downfield compared to those 
deriving from the 3-MeO and 4-MeO counterparts and a similar effect was observed in the 13C 
spectra. The proton chemical shifts linked to the 3,5 and β-positions on the other hand were 
equivalent in all three positional isomers. This effect was observed with the corresponding PCP 
HCl salt series[30] although it was not consistently observed with the N-alkyl secondary anisyl-
cyclohexylamines.[5]  
NMDAR and off-target receptor binding studies 
With regards to NMDAR, the results of competitive [3H]-MK-801 displacement assays are 
provided in Table 3 as IC50 and Ki values and shown graphically in Figure 6.  Compared to some 
previously investigated PCP analogs,[30] substitution of piperidine for a morpholine ring reduced 
NMDAR affinity. Consistent with the present results, PCMo was previously reported to show a 
~10 fold reduced affinity to NMDAR using [3H]-PCP in central nervous system tissue.[18,46] 
Furthermore, PCMo had 10-fold reduced potency relative to PCP in a number of experimental 
models.[46,47] The affinity rank order determined in this study was comparable to their PCP 
counterparts with 3-MeO > H > 2-MeO > 4-MeO).[30] Interestingly, the same affinity order was  
seen with a series of diphenidine analogs,[4] although it was not observed with the methoxylated 
PCPy series (3-MeO > 4-MeO > 2-MeO).[30]  
A heatmap containing the results of the binding experiments on the 46 assessed CNS receptors 
is presented in Figure 7. Besides NMDAR, all compounds had moderate affinity for the sigma-2 
receptor, which is commonly seen with this class of compounds.[4,30,48] 3,4-MD-PCMo was the 
most selective compound and this selectivity was consistent with other 3,4-MD substituted 
arylcyclohexylamines.[30] Likewise, 3,4-MD-PCMo and PCMo had moderate NMDAR affinity 
values comparable to ketamine and memantine.[4,49,50] PCMo was shown to be less potent and 
toxic than PCP,[24]  which may be explained by the moderate NMDAR affinity.[30,49,50]  
Arylcyclohexylamines have displayed variable affinities at the monoamine reuptake transporters 
for serotonin, norepinephrine, and dopamine (SERT, NET, and DAT, respectively).[30,51] 
Interestingly, the morpholine ring abolished NET activity for all compounds relative to their 
piperidine counterparts.[30] 3-Me-PCMo was the only compound with affinity for both SERT and 
DAT. The 2-MeO and 3-MeO analogues displayed selectivity towards SERT over DAT, whereas 
4-MeO-PCMo had appreciable affinity for DAT.  
Larger 1,4-diaminocyclohexane derivatives containing the PCMo moiety displayed in vitro µ-
opioid receptor activity in previous cell-based assays.[52] However, the binding experiments in 
this study revealed no affinity for the δ-, κ- or µ-opioid receptors, which indicate that the anti-
nociceptive properties may have been the result of NMDAR antagonism.[53-56] Previous 
pharmacological experiments with PCMo, 2-MeO-PCMo, 4-Me-PCMo, and 2-Me-4-HO-PCMo 
found analgesic activity in rats[17] which further suggests analgesic effects being mediated 
independently from opioid receptor affinity.  
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Conclusion 
4-[1-(3-Methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo), a morpholine analogue of 3-
MeO-PCP, is available for purchase as a “research chemical” and suspected to share some 
psychopharmacological  properties with ketamine and perhaps phencyclidine (PCP). The 
present study described the analytical characterization of 3-MeO-PCMo, its two positional 
isomers and three additional analogues. Differentiation between 2-MeO-, 3-MeO- and 4-MeO-
PCMo was detectable by chromatographic and spectroscopic methods. In vitro pharmacological 
investigations also revealed that the compounds displayed moderate affinity toward the N-
methyl-D-aspartate receptor with off-target activities at sigma-2 and monoamine transporters for 
dopamine and serotonin. These findings suggest that at least some of the investigated 
arylcyclohexylmorpholines, including 3-MeO-PCMo, may be psychoactive in humans and thus 
have abuse potential which may account for some of the purchases of this “research chemical.” 
Clinical and forensic studies would be required to investigate this hypothesis further.  
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Figure Captions 
 
Figure 1. A: Examples of psychoactive substances with dissociative profiles. B: Morpholine 
analogs investigated in the present study. The numbering scheme employed for 13C NMR 
assignments is shown for the isomers substituted with methoxy groups.  
Figure 2.  Synthetic scheme used to for the preparation of the investigated PCMo series via the 
modified Geneste route.[5,10,32] TFA: trifluoroacetic acid; TEA: triethylamine. R = 2-, 3-, and 4-
MeO, 3,4-OCH2O, 3-Me or H. 
Figure 3. Gas chromatography ion trap mass spectrometry (GC-IT-MS) data obtained from 
electron ionization (EI) and chemical ionization (CI) methods. 
Figure 4. Ultra-high performance liquid chromatography high mass accuracy electrospray 
tandem mass spectra. 
Figure 5. Diode array ultraviolet full scan spectra and high performance liquid chromatography 
data for 2-, 3- and 4-MeO-PCMo.  
Figure 6. Competitive binding curves for PCP, PCMo, and analogues from [3H]-MK-801 
displacement using rat forebrain homogenate.  
Figure 7. Heatmap of compound affinities (Ki) at CNS receptors. Solid green without number 
indicates IC50 was >10,000 nM in primary assay. 
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Figure 6. Competitive binding curves for PCP, PCMo, and analogues from [3H]-MK-801 displacement using 
rat forebrain homogenate.  
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Figure 7. Heatmap of compound affinities (Ki) at CNS receptors. Solid green without number indicates IC50 
was >10,000 nM in primary assay.  
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Table 1. 
1
H NMR data for PCMo freebases in CDCl3 
Proton 2-MeO- PCMo 3-MeO- PCMo 4-MeO- PCMo 3,4-MD-PCMo 3-Me-PCMo PCMo 
H1 - - - - - - 
H2,6 2.64–2.55 m  
(2Heq) 
 
1.80 ddd 
 (J = 13.6, 10.5, 3.0 
Hz, 2Hax) 
2.13–2.03 m 
(2Heq) 
 
1.93 ddd  
(J = 13.3, 9.5, 3.3 
Hz, 2Hax) 
2.15–2.05 m 
(2Heq) 
 
1.91 ddd  
(J = 13.4, 9.7, 
3.3 Hz, 2Hax) 
2.08–1.97 m  
(2Heq) 
 
1.89 ddd 
(J = 13.3, 9.6, 3.3 
Hz, 2Hax) 
2.15–2.04 m 
(2Heq) 
 
1.94 ddd 
(J = 13.4, 9.4, 
3.3 Hz, 2Hax) 
2.19–2.04 m 
(2Heq) 
 
1.95 ddd 
(J = 13.5, 
9.6, 3.4 Hz, 
2Hax) 
H3,5 1.74–1.61 m  
(2Heq) 
 
1.32–1.20 m  
(2Hax) 
1.74–1.65 m  
(2 Heq) 
 
1.38–1.27 m  
(2 Hax) 
1.74–1.64 m  
(2 Heq) 
 
1.35–1.23 m  
(2 Hax) 
1.74–1.63 m  
(2 Heq) 
 
1.39–1.25 m  
(2 Hax) 
1.76–1.66 m  
(2 Heq) 
 
1.37–1.26 m  
(2 Hax) 
1.76–1.64 m 
(2Heq) 
 
1.39–1.24 m 
(2Hax) 
H4 1.51–1.32 m  
(2H) 
1.47–1.40 m  
(2H) 
1.49–1.39 m 
(2H) 
1.49–1.39 m  
(2H) 
1.48–1.39 m 
(2H) 
1.50–1.39 m 
(2H) 
H1’ - - - - - - 
H2’ - 6.85 t 
(J = 1.9 Hz, 1H) 
7.21 dm  
(J = 8.9 Hz, 1H) 
6.79 d 
(J = 8.3 Hz, 1H) 
7.10 s  
(1H) *overlap 
with H6’ 
7.32–7.27 m 
(1H) 
H3’ 6.98–6.88 m  
(1H) 
- 6.88 dm 
 (J = 8.9 Hz, 1H) 
- - 7.38–7.32 m 
(1H) 
H4’ 7.29–7.18 m  
(1H) 
6.79 dd 
(J = 8.1, 2.5 Hz, 
1H) 
- - 7.10–7.06 m 
(1H) *overlap 
with H2’ 
7.27–7.20 m 
(1H) 
H 5’ 6.98–6.88 m  
(1H) 
7.27 t 
(J = 8.0 Hz, 1H) 
6.88 dm  
(J = 8.9 Hz, 1H) 
6.82 d 
(J = 1.8 Hz, 1H) 
7.30–7.19 m 
(1H) 
7.38–7.32 m 
(1H) 
H6’ 7.29–7.18 m  
(1H) 
6.89 dd 
(J = 7.8, 1.8 Hz, 
1H) 
7.21 dm 
 (J = 8.9 Hz, 1H) 
6.75 dd 
(J = 8.3, 1.8 Hz, 1H) 
7.05 dm 
(J = 7.6 Hz, 1H) 
7.32–7.27  m 
(1H) 
Hα 2.43 t 
(J = 4.5 Hz, 4H) 
2.34 t 
(J = 4.6 Hz, 4H) 
2.32 t 
(J = 4.6 Hz, 4H) 
2.33 t 
(J = 4.5 Hz, 4H) 
2.33 t 
(J = 4.6 Hz, 4H) 
2.33 t 
(J = 4.5 Hz, 
4H) 
Hβ 3.63 t 
(J = 4.6 Hz, 4H) 
3.63 t 
(J = 4.6 Hz, 4H) 
3.63 t 
(J = 4.6 Hz, 4H) 
3.63 t 
(J = 4.6 Hz, 4H) 
3.63 t 
(J = 4.7 Hz, 4H) 
3.63 t 
(J = 4.6 Hz, 
4H) 
Cc 3.77 s (OCH3) 3.82 s (OCH3) 3.81 s (OCH3) 5.95 s (OCH2O) 2.37 s (CH3) - 
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Table 2. 
13
C NMR data for PCMo analogues (freebase, in CDCl3) 
Carbon 2-MeO-PCMo 3-MeO-PCMo 4-MeO-PCMo 3,4-MD-PCMo 3-Me-PCMo PCMo 
C1 63.12 60.69 60.35 60.72 60.62 60.71 
C2,6 34.49 33.00 33.00 33.21 32.93 32.86 
C3,5 22.93 22.29 22.28 22.29 22.28 22.25 
C4 26.46 26.26 26.32 26.27 26.33 26.31 
C1’ 126.91 141.18 131.37 133.70 139.16 139.22 
C2’ 159.75 114.34 128.52 107.23 127.99 127.34 
C3’ 112.43 159.19 112.87 147.41 136.97 127.64 
C4’ 130.52 110.51 157.87 145.72 124.47 126.35 
C5’ 119.97 128.45 112.87 107.97 127.48 127.64 
C6’ 127.92 119.95 128.52 120.66 127.06 127.34 
Cα 46.64 45.91 45.84 45.88 45.88 45.86 
Cβ 68.13 67.88 67.84 67.86 67.89 67.87 
Cc 55.16 (OCH3) 55.17 (OCH3) 55.14 (OCH3) 100.82 (OCH2O) 21.86 (CH3) - 
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Table 3. NMDAR binding affinities for PCMo series using [
3
H]-MK-801 in 
rat forebrains. Means ± SEM from three separate experiments run in 
duplicate.   
Compound IC50 ± SEM (nM) Ki ± SEM (nM) 
PCP 34.7 ± 2.5 22.1 ± 1.6 
Ketamine 
[4] 
508.5 ± 30.1
[4] 
323.9 ± 19.2
[4] 
2-MeO-PCMo 2,477 ± 115 1,578 ± 73.2 
3-MeO-PCMo 397.0 ± 45.4 252.9 ± 28.9 
4-MeO-PCMo 3,326 ± 343.3 2,118 ± 218.7 
3,4-MD-PCMo 668.0 ± 30.5 425.5 ± 19.4 
3-Me-PCMo  316.8 ± 29.1 201.8 ± 18.5 
PCMo  524.6 ± 13.7 334.1 ± 8.8 
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